Study of Brimonidine and Timolol Ophthalmic Solution With Latanoprost Compared With Latanoprost in Glaucoma Patients
Status:
Terminated
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of patients switched from latanoprost
monotherapy to a combination therapy of latanoprost with COMBIGAN® (brimonidine 0.2%/timolol
0.5% fixed combination ophthalmic solution) for chronic angle closure glaucoma.